Alector, Inc. announced a significant workforce reduction of about 49% as part of its strategic realignment on October 21, 2025, impacting around 75 employees, with restructuring costs estimated at $7.7 million. This decision follows the discontinuation of the clinical trial for its product candidate, latozinemab, due to trial results.